

Leukemia

Basis of classification

Stem cell: CD34 & TDT	Myeloid: MPO , CD13, CD33, CD14, CD64, CD41 (M7) & CD235a (M6)	B-lymphoid: CD10, CD19 , CD22 , CD79a T-lymphoid: CD3 , CD4, CD5, CD7, CD8
--	---	--

Acute leukemia

Immature cells | >20% blasts | Auer rods | | T-ALL: mediastinal & CNS lesions | AML: adults | ALL: child

AML		ALL	
Karyotype	Molecular	Karyotype	Molecular
t (8;21) (M2) (Granulated blasts often with Auer rods)	AML1-ETO	t (9;22) Hypodiploidy (worse prognosis)	BCR-ABL1
t (15;17) (M3) (Promyelocytic leukaemia) Rx: ATRA or arsenic .	PML-RARA (DIC)	t (4;11)	AF4-MLL
t (16;16) or inv. (16) (M4) (Myelomonocytic leukaemia)	CBFB-MYH11 (Gum hyperplasia)	t (12;21) Hyperdiploidy (better prognosis)	ETV6-RUNX1
t (9;11) (M5) (Monocytic leukaemia)	MLL1-MLL (Gum hyperplasia)	t (5;14)	IL3-IGH

Chronic leukemia

Adults (old) | Mature cells (granulocytes) | Lymphoid (LPN-CLL) | Myeloid (MPN (CML) \ MDS)

MPN features:	- Cytoses , splenomegaly , high uric acid , hypercellular BM , progress to acute leukemia (mainly AML) (CML belongs to MPN)
----------------------	---

CML

- Stem cell MPN.
- Associated w\ **BCR-ABL1** in the **Philadelphia (Ph)** chromosome → t (9;22) → ↑ tyrosin kinase activity. → treated w\ **Imatinib**.
- Predominant granulocytic cells.

Clinical presentation	<ul style="list-style-type: none"> - 20-40% are Asymptomatic. - CBC: marked leukocytosis. - Fatigue, weight loss, night sweating. - Abdominal discomfort → splenomegaly (massive). 		
Main differential dx		Chronic myelomonocytic leukemia CMML → monocytosis , BCR-ABL1 -ve .	
		Leukemoid reaction → leukocytosis due to physiological response to stress or infection.	
		CML	Leukimoid
	WBC	Very high	High, but <100,000
	differential	Myelocytes & segmented neutrophils	Bands neutrophils & neutrophils
	Morphology	Hypogranular	Toxic granulation
	Splenomegaly	+ve	Mainly -ve
NAP score	Low	High	
BCR-ABL	+ve	-ve	

	Chronic phase	Accelerated phase	Blastic phase
CML phases	<ul style="list-style-type: none"> - Leukicytosis - Blasts ≤10%, basophils ≤20% - Stable course (yrs) 	<ul style="list-style-type: none"> - 10-19% blasts, basophils ≥ 20%. - Unstable course. 	<ul style="list-style-type: none"> - ≥ 20% blasts = acute leukemia - 80% = AML, 20% ALL. - Course: weeks

Myelodysplastic Syndromes MDS

Features	<ul style="list-style-type: none"> - Group of myeloid neoplasms. - Peripheral cytopenia (How Hb ± low WBC & low PLT) = pancytopenia MPN عكس - ↑ proliferation – ↑ apoptosis = Ineffective hematopoiesis (hypercellular BM) تموت قبل لا تطلع - Dysplasia (abnormal morphology) - Progression to AML. - Enhanced apoptosis.
----------	--

MDS subtypes Many subtypes according to:	1- Blast count	2- Degree of dysplasia	3- Genetics → -5, -7 (deletion in these chrom.)
---	----------------	------------------------	---

Chronic Myelomonocytic Leukemia (CMML)

Features	<ul style="list-style-type: none"> - Clonal hematopoietic malignancy, characterized by proliferation of both monocytes & neutrophils. - MDS\MPN disease: CMML يجون مع • Features of MDS (dysplasia, enhances apoptosis) • Features of MPN (marked proliferation) - Philadelphia chromosome must be negative! - Blasts must be < 20% (less). - It has an aggressive course.
----------	--

Lymphoid leukemia

CLL | Hairt cell leukemia | T-prolymphocytosis leukemia | leukemic phase of lymphoma

CLL

Features	<ul style="list-style-type: none"> - Small, mature lymphocytes in the blood & BM (± spleen and lymph node) - Most common adult leukemia. (25% of adult leukemias) → 55-65 yrs. Rare <40yrs. Male more. - 40% asymptomatic. - Moderate lymphadenopathy & splenomegaly. - Lymphocytosis (>5,000) - Morphology: small mature appearing lymphocytes → <ul style="list-style-type: none"> ○ Condensed (soccer ball) nuclear chromatin. ○ Numerous (smudge cells) إذا ميب فيه لازم أصير وأستقي لما تصير سنستف عشان أقول إنها CLL - Predisposition to infection. - Autoimmune phenomena → autoimmune hemolytic anemia. - Transformation to DLBCL (Richter's syndrome)
Markers	- CD5, CD23, CD20, CD19, IgM & IgD → Mature naïve B-cell

Lymphoma		
Mature cells	Lymphoid leukemia	Discussed above.
	Lymphoma	Non-Hodgkin lymphoma <u>B cell:</u> - Burkitt's lymphoma - DLBL - Follicular lymphoma. - Multiple myeloma <u>T cell:</u> - Adult T leukemia lymphoma. - Sezary syndrome. - Large anaplastic T lymphoma.
		Hodgkin lymphoma - presence of few large binucleated cells (Reed-Sternberg) surrounded by reactive cells (lympo, plasma, eosinophils) - Involving cervical lymph nodes in <u>young adults</u> . - CD30 & CD15.

Burkitt's lymphoma

High grade | Fastest growing tumor in human (24hs) & highly aggressive | **t(8;14) c-MYC at 8 with Ig at 14** c-myc: (nuclear transcription factor) (proto-oncogen)

Types of Burkitt's lymphoma

1- Endemic	2- Sporadic	3- Immunodeficiency-associated
w\ chronic malarium EBV → Africa. Affects the jaw & facial bone & breast.	Throughout the world, affects GIT	HIV & immunosuppressive drugs

Morphology
 - BMA: Homogenous medium size, deeply basophilic, **vacuolated** cytoplasm.
 - Biopsy: Diffused infiltration w\ **Starry sky** (macrophage engulfing the apoptotic cells)

Follicular lymphoma

Proliferation of **germinal center B cells centrocyte** | over expression of **Bcl2** by **t(14;18)** | **most common type of indolent lymphoma → but it is incurable ☹**

Presenting problem	<ul style="list-style-type: none"> ✓ Lymphadenopathy (100%) ✓ Splenomegaly (80%) ✓ BM involvement (40%) ✓ Blood involvement (40%) 	Diagnosis	<ul style="list-style-type: none"> - Positive for CD10, CD20 & Bcl2. - Negative for CD5.
--------------------	---	-----------	--

Multiple myeloma

Triad of abnormalities: 1- **Accumulation** of **plasma cells in BM.** 2- **Lytic bone lesions** أكثر شيء في الجمجمة
 3- Production of a **monoclonal immunoglobulin (Ig)**

Markers of Lymphoproliferative disorders

	CD34 & TDT	s-Ig	CD19	CD20	CD5	CD10
ALL	+	-	+	+	-	-
CLL	-	+	+	+	+	-
Mantle lymphoma t(11;14) cyclin D	-	+	+	+	+	-
Burkitt's lymphoma t(8;14) c-myc	-		+		-	+
DLBCL t(3;14) Bcl-6						
Follicular lymphoma t(14;18) Bcl-2						
Multiple myeloma (CD38, CD138, IgG, IgA, IgE)	-	+	-	+	-	-